Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
मुख्य लेखकों: | Pellagatti, A, Jadersten, M, Forsblom, A, Cattan, H, Christensson, B, Emanuelsson, E, Merup, M, Nilsson, L, Samuelsson, J, Sander, B, Wainscoat, J, Boultwood, J, Hellstrom-Lindberg, E |
---|---|
स्वरूप: | Conference item |
प्रकाशित: |
2006
|
समान संसाधन
-
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
द्वारा: Pellagatti, A, और अन्य
प्रकाशित: (2007) -
Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
द्वारा: Jadersten, M, और अन्य
प्रकाशित: (2005) -
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
द्वारा: Jädersten, M, और अन्य
प्रकाशित: (2009) -
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
द्वारा: Scharenberg, C, और अन्य
प्रकाशित: (2011) -
Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
द्वारा: Pellagatti, A, और अन्य
प्रकाशित: (2009)